Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;5 Suppl 6(Suppl 6):S3-9.

Prostate cancer: epidemiology and screening

Timothy J Wilt

Prostate cancer: epidemiology and screening

Timothy J Wilt. Rev Urol. 2003.

Abstract

The 13th International Prostate Cancer Update provided an overview of diagnosis, treatment, and management strategies in prostate cancer. This article provides a summary of the reports presented during the epidemiology and screening session. Methods to improve early detection and treatment are being developed. Proposed refinements to prostate-specific antigen (PSA) testing include the use of age-specific PSA levels, PSA velocity, prostate volume-adjusted PSA densities, free-to-total PSA ratios, and complexed PSA. Optimal follow-up screening intervals for persons who elect PSA testing and are found to have initially normal levels have been proposed. Molecular oncology is becoming increasingly important in understanding the development and progression of prostate cancer as well as identifying new therapeutic targets for hormone-refractory disease. Nomograms that include PSA levels, histologic grade, and the extent of the tumor have been developed to optimize management decisions. Despite advances in early detection and treatment, controversy persists because of the lack of evidence demonstrating that they improve length and quality of life. Until results from randomized trials are completed, clinicians should provide patients with balanced information that incorporates the potential risks and benefits of screening and treatment and individual preferences for various outcomes.

PubMed Disclaimer

References

    1. World Health Organization, authors. The World Health Report. 1999. Available at: http://www.who.org/whr.
    1. U.S. Preventive Services Task Force, authors. Screening for Prostate Cancer: Recommendations and Rationale. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Originally published in Ann Intern Med 2002;137:915–916.
    1. Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am. 1997;24:353–365. - PubMed
    1. Labrie F, DuPont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992;147:846–852. - PubMed
    1. Mettlin C, Littrup PJ, Kane RA, et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with agereferenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1994;74:1615–1620. - PubMed

LinkOut - more resources